We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-11.64%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
-$306M
Cap. Flow
-$59.1M
Cap. Flow %
-5.47%
Top 10 Hldgs %
66.39%
Holding
80
New
21
Increased
8
Reduced
13
Closed
16

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
2
MRK icon
Merck
MRK
+$18.4M
3
ALGN icon
Align Technology
ALGN
+$11.1M
4
HRTX icon
Heron Therapeutics
HRTX
+$8.1M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$6.87M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.4M
3
FATE icon
Fate Therapeutics
FATE
+$15.1M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$136M 12.56%
1,885,602
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.7B
$125M 11.56%
1,109,874
– –
NXTC icon
3
NextCure
NXTC
$17.3M
$99M 9.16%
222,655
– –
NTRA icon
4
Natera
NTRA
$37.5B
$92.6M 8.56%
3,100,560
– –
PRNB
5
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$84.2M 7.78%
1,417,258
– –
YMAB
6
DELISTED
Y-mAbs Therapeutics
YMAB
$57.3M 5.3%
2,194,278
– –
MRK icon
7
Merck
MRK
$324B
$35.7M 3.3%
486,057
+233,692
+93% +$18.4M
CHRS icon
8
Coherus Oncology
CHRS
$217M
$31.4M 2.9%
1,933,221
– –
GRTX
9
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$29.3M 2.71%
3,083,712
– –
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$27.6M 2.55%
+307,300
New +$30.2M
MRUS
11
DELISTED
Merus
MRUS
$23.7M 2.19%
1,961,039
– –
UTHR icon
12
United Therapeutics
UTHR
$26.3B
$22.1M 2.05%
233,559
+44,914
+24% +$4.27M
AMRN
13
Amarin Corp
AMRN
$284M
$20.8M 1.93%
260,415
– –
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$121B
$20.4M 1.89%
85,664
-53,500
-38% -$12.3M
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$11.5B
$20.3M 1.88%
240,046
-201,826
-46% -$17.4M
BIIB icon
16
Biogen
BIIB
$29.9B
$16.6M 1.54%
52,628
-11,083
-17% -$3.36M
XLRN
17
DELISTED
Acceleron Pharma
XLRN
$14.8M 1.37%
165,160
+18,128
+12% +$1.41M
KNSA icon
18
Kiniksa Pharmaceuticals
KNSA
$4.83B
$14.3M 1.32%
922,700
– –
NCNA
19
NuCana
NCNA
$5.37M
$13.2M 1.22%
453
– –
PTCT icon
20
PTC Therapeutics
PTCT
$6.37B
$13M 1.21%
292,217
-224,875
-43% -$11.3M
OBSV
21
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.4M 1.06%
4,749,623
– –
SRPT icon
22
Sarepta Therapeutics
SRPT
$1.66B
$9.94M 0.92%
101,603
+13,785
+16% +$1.58M
KALA icon
23
KALA BIO
KALA
$11.8M
$9.8M 0.91%
446
+180
+68% +$2.88M
MYOK
24
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$8.21M 0.76%
175,118
-20,753
-11% -$1.33M
ALGN icon
25
Align Technology
ALGN
$12B
$8.09M 0.75%
+46,500
New +$11.1M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2020 Portfolio in Review

As of Q1 2020, Sofinnova Investments held 80 positions worth $1.08B, down 22% from $1.39B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sofinnova Investments withdrew a net $59.1M in Q1 2020, closing 16 positions and reducing 13 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Alexion Pharmaceuticals worth $27.6M.

  • Sofinnova Investments's largest Q1 2020 buy was Alexion Pharmaceuticals: 307,300 shares worth $27.6M.
  • Sofinnova Investments added most to Merck in Q1 2020, an estimated $18.4M increase.
  • Sofinnova Investments's biggest Q1 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $17.4M.
  • Sofinnova Investments fully exited Regeneron Pharmaceuticals in Q1 2020, selling an estimated $18.8M.
  • Sofinnova Investments's ten largest holdings make up 66% of its $1.08B portfolio in Q1 2020.
  • Sofinnova Investments opened 21 new positions and closed 16 in Q1 2020.
  • Sofinnova Investments's portfolio value fell 22% quarter-over-quarter to $1.08B.

Based on Sofinnova Investments's 13F filing for Q1 2020, filed 13 May 2020.